Skip to main content

Table 2 Clinical and economic burden of severe asthma during the 1-year follow-up period

From: Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data

 

All patients with severe asthma

Patients with severe asthma stratified by eosinophil counts

< 300 cells/µL

≥ 300 cells/µL

N = 212

n = 33

n = 23

New prescriptions, n (%)

 OCS

23 (11)

5 (15)

2 (9)

 SABA

138 (65)

20 (61)

11 (48)

Physician visits, mean (SD)

7 (6)

10 (8)

10 (7)

Respiratory specialist referral, n (%)

20 (9)

4 (12)

4 (17)

Number of laboratory tests, mean (SD)

18 (36)

34 (51)

46 (51)

Number of sick notes, mean (SD)

0.3 (1.1)

0.5 (1.6)

0.3 (0.7)

Physician billing [Can $], mean (SD)

369 (373)

517 (396)

620 (646)

  1. Can $ Canadian $, OCS oral corticosteroid, SABA short-acting β2-agonist, SD standard deviation